Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended January 31, 2023. Champions Oncology provides technology-enabled oncology research and drug-development services, including pharmacology studies, biomarker and data platforms, and Lumin Bioinformatics.
Financial performance
| Metric | Three months ended Jan. 31, 2023 | Prior-year quarter | Nine months ended Jan. 31, 2023 | Prior-year nine months |
|---|---|---|---|---|
| Oncology services revenue | $12.8 million | $13.2 million | $40.8 million | $36.2 million |
| Gross margin | 39.7% | 51.4% | 45.6% | 51.9% |
| Operating income (loss) | $(2.5) million | $0.8 million | $(2.7) million | $0.9 million |
| Net income (loss) | $(2.4) million | $0.8 million | $(2.8) million | $0.9 million |
| Diluted earnings (loss) per share | $(0.18) | $0.05 | $(0.20) | $0.06 |
| Operating cash flow | Quarterly amount: $1.6 million, per MD&A | Not stated | $4.7 million | $5.7 million |
All dollar figures are in U.S. dollars. Revenue increased 12.6% year to date but declined 3.2% in the quarter. Nine-month expenses grew faster than revenue: total costs and operating expenses rose 23.3% to $43.5 million. R&D expense increased 28.2% year to date to $8.7 million, primarily due to compensation and lab supplies for investment in the therapeutic drug-discovery platform.
Balance sheet and liquidity
At January 31, 2023, cash was $11.6 million, current assets were $20.4 million, and total assets were $36.2 million. Current liabilities were $20.8 million, including $13.2 million of deferred revenue. Stockholders’ equity was $7.1 million, down from $9.1 million at April 30, 2022. The accumulated deficit was $74.8 million.
The filing reports no off-balance-sheet debt or similar obligations. Operating lease liabilities totaled approximately $8.9 million; the filing also describes laboratory-equipment finance leases. Management states cash on hand and expected fiscal 2023 operating cash flows are adequate to fund operations for at least 12 months from the filing date. If revenue expectations are not met, management says it could implement cost reductions; additional capital may be needed, with no assurance it could be raised on acceptable terms.
Material changes and management commentary
- Quarterly revenue fell because cancellations increased on studies booked in prior quarters. Management said strong bookings did not convert to revenue at the expected rate.
- Cost of oncology services rose 20.2% in the quarter and 27.5% year to date, mainly from compensation for pharmacology study teams staffed to support expected bookings growth. Management attributed lower gross margins to this cost increase and cancellations.
- Nine-month revenue growth was primarily attributed to demand and platform expansion supporting larger in-vivo and ex-vivo pharmacology studies.
- Sales and marketing expense rose with compensation and conference costs supporting expanded sales efforts; general and administrative expense increased mainly with compensation and IT costs.
- Investing cash outflow was $2.1 million, primarily for laboratory and computer equipment. Cash increased $2.6 million over the nine-month period.
Outlook, risks, and other items
No numerical revenue or earnings guidance is provided. Management’s stated liquidity outlook depends on revenue expectations and expected operating cash flows. Important risks include customer study cancellations, failure of expected revenue or bookings to materialize, potential difficulty raising capital, and cash balances held above FDIC insurance limits. The company disclosed $10.9 million of cash above FDIC-insured limits at January 31, 2023. It reported no known material legal proceedings and no accrued registration-rights penalties. A new Italian lease consolidated office and laboratory space; the company also recognized a laboratory-equipment finance lease during the period.
Important facts for investors to verify
- Whether study cancellations continue and whether bookings convert into recognized revenue.
- Whether staffing and other operating costs can be aligned with realized demand and gross margins recover.
- Whether operating cash generation remains sufficient to fund research investment and working capital needs.
- The duration and financial impact of lease commitments, and exposure to uninsured bank deposits.
- Progress and spending on the therapeutic drug-discovery platform and Lumin, including any future financing or strategic transactions.